Neonatal Pharmacology Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Neonatal Pharmacology. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Neonatal Pharmacology Indian Medical PG Question 1: Which of the following drugs can cause ototoxicity?
- A. Metronidazole
- B. Amoxicillin
- C. Ciprofloxacin
- D. Amikacin (Correct Answer)
Neonatal Pharmacology Explanation: ***Amikacin***
- **Amikacin** is an **aminoglycoside antibiotic** and is **the most well-known** drug among the options for causing **ototoxicity** (damage to the ear, leading to hearing loss, tinnitus, or vestibular dysfunction) [1], [2].
- This adverse effect is **dose-dependent** and related to the **cumulative dose** and **peak plasma levels** of the drug [2].
- Aminoglycosides cause both **cochlear toxicity** (hearing loss) and **vestibular toxicity** (balance problems) [1], [2].
*Metronidazole*
- **Metronidazole** is an antibiotic and antiprotozoal drug that primarily causes **gastrointestinal upset** and a **metallic taste** in the mouth.
- While it can cause neurological side effects like **peripheral neuropathy**, **ototoxicity is not a typical adverse effect** associated with metronidazole.
*Amoxicillin*
- **Amoxicillin** is a common **penicillin-class antibiotic** generally considered safe with a good side effect profile.
- Its most common side effects are **gastrointestinal disturbances** like nausea, vomiting, and diarrhea, as well as **allergic reactions** and skin rashes.
- **Ototoxicity is not a recognized side effect** of beta-lactam antibiotics.
*Ciprofloxacin*
- **Ciprofloxacin** is a **fluoroquinolone antibiotic** primarily associated with side effects like **tendinopathy**, **arthropathy**, and **QT prolongation**.
- While fluoroquinolones **can cause ototoxicity** (tinnitus, hearing disturbances), this is **much less common and less severe** compared to aminoglycosides.
- Ciprofloxacin is not the primary drug associated with ototoxicity in this context.
Neonatal Pharmacology Indian Medical PG Question 2: Which of the following drugs can cause cartilage damage in children?
- A. Cotrimoxazole and other sulfonamides
- B. Penicillin and other beta-lactams
- C. Metronidazole and other nitroimidazoles
- D. Ciprofloxacin and other fluoroquinolones (Correct Answer)
Neonatal Pharmacology Explanation: ***Ciprofloxacin and other fluoroquinolones***
- Fluoroquinolones, including ciprofloxacin, are known to cause **arthropathy** (joint disease) and **cartilage damage** in growing children and adolescents [1].
- This adverse effect has limited their use in pediatric populations, typically reserved for severe infections where other effective and safer alternatives are unavailable [1].
*Cotrimoxazole and other sulfonamides*
- Sulfonamides are primarily associated with adverse effects like **hypersensitivity reactions** (e.g., Stevens-Johnson syndrome), **bone marrow suppression**, and **crystalluria**.
- They are not typically linked to cartilage damage in children.
*Penicillin and other beta-lactams*
- Penicillins and other beta-lactam antibiotics are generally considered **safe in children** and are a common choice for pediatric infections.
- Their primary adverse effects are hypersensitivity reactions, such as **rashes** or **anaphylaxis**, and gastrointestinal disturbances, not cartilage damage.
*Metronidazole and other nitroimidazoles*
- Metronidazole's main adverse effects include **gastrointestinal upset**, **metallic taste**, and **neurological symptoms** (e.g., peripheral neuropathy, seizures with high doses).
- There is no known association between metronidazole and cartilage damage in children.
Neonatal Pharmacology Indian Medical PG Question 3: Newborns as compared to adults eliminate lidocaine:
- A. Variable
- B. More rapidly
- C. Equally fast
- D. More slowly (Correct Answer)
Neonatal Pharmacology Explanation: ***More slowly***
- Newborns have **immature hepatic enzyme systems**, particularly for **CYP1A2** and **CYP3A4**, which are crucial for lidocaine metabolism.
- Reduced **plasma protein binding** and a larger **volume of distribution** in newborns can also impact lidocaine clearance, leading to slower elimination.
*Variable*
- While there can be individual variability in drug metabolism, the general trend for lidocaine elimination in newborns is consistently slower due to physiological immaturity, not merely variable.
- This option does not capture the overall physiological characteristic of drug elimination in neonates.
*More rapidly*
- This is incorrect because newborns have underdeveloped liver function and enzyme systems, which would hinder, not accelerate, the metabolism and elimination of drugs like lidocaine.
- A more rapid elimination would suggest a highly efficient metabolic pathway, which is not the case in neonates.
*Equally fast*
- This is incorrect as the **pharmacokinetic profile** of drugs, including lidocaine, differs significantly between newborns and adults due to developmental differences in organ function (e.g., liver, kidneys).
- The liver's metabolic capacity in newborns is not fully mature enough to eliminate lidocaine at the same rate as in adults.
Neonatal Pharmacology Indian Medical PG Question 4: A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
- A. 20 liter/hr
- B. K is 0.0693
- C. 0.22 L/hr (Correct Answer)
- D. 0.02 L/hr
Neonatal Pharmacology Explanation: ***0.22 L/hr***
- To calculate clearance at steady state, we use the formula: **Clearance (Cl) = Dose Rate / Css** (steady-state plasma concentration).
- **Dose rate calculation**: 100 mg/kg × 70 kg × 2 doses/day = 14,000 mg/day = 583.33 mg/hr
- **Converting plasma concentration**: 1.9 mg/mL = 1900 mg/L
- **Clearance calculation**: Cl = 583.33 mg/hr ÷ 1900 mg/L = **0.307 L/hr**
- **Note**: The calculated value (0.307 L/hr) does not exactly match any option. The marked answer (0.22 L/hr) is the closest approximation among the given choices. This discrepancy may arise from rounding in the original question parameters or implicit assumptions about bioavailability/volume of distribution.
*0.02 L/hr*
- This value is approximately 15 times lower than the calculated clearance.
- Such low clearance would result in much higher plasma concentrations or require significantly lower dosing.
*20 liter/hr*
- This clearance is approximately 65 times higher than calculated, representing an unrealistically high value for this scenario.
- Such high clearance would result in very low plasma concentrations unless extremely high doses were administered.
*K is 0.0693*
- This represents the **elimination rate constant (k)**, calculated as k = 0.693/t1/2 = 0.693/10 hr = 0.0693 hr⁻¹.
- While mathematically correct for k, the question specifically asks for **clearance**, not the elimination rate constant.
- Clearance is related to k by: Cl = k × Vd (volume of distribution).
Neonatal Pharmacology Indian Medical PG Question 5: A term neonate, with a birth weight of 2700 g, who is otherwise well, and is exclusively breastfed, presents for routine evaluation. His total serum bilirubin is found to be 14mg/dl on day 5. What is the management?
- A. No active treatment required (Correct Answer)
- B. Stop breastfeeding for 2 days
- C. Phototherapy
- D. Exchange transfusion
Neonatal Pharmacology Explanation: ***No active treatment required***
- A total serum bilirubin of **14 mg/dL** on day 5 in an otherwise well, exclusively breastfed term neonate (birth weight 2700g, which is >2500g) falls within the **physiologic jaundice range** and below thresholds for intervention.
- This level is considered **normal for breastfed infants** at this age and does not warrant medical intervention as per current guidelines.
*Stop breastfeeding for 2 days*
- This intervention, known as **breast milk jaundice interruption**, is usually reserved for higher bilirubin levels or if there is concern for significant breast milk jaundice, which is not indicated here.
- Temporarily stopping breastfeeding can disrupt the establishment of breastfeeding and is generally discouraged unless strictly necessary.
*Phototherapy*
- **Phototherapy** is indicated for bilirubin levels typically >15-18 mg/dL in a healthy term neonate on day 5, depending on risk factors, which this infant does not meet.
- It works by converting unconjugated bilirubin into water-soluble isomers that can be excreted more easily.
*Exchange transfusion*
- **Exchange transfusion** is reserved for severe hyperbilirubinemia, usually with bilirubin levels approaching or exceeding 20-25 mg/dL, especially if there are signs of **acute bilirubin encephalopathy**.
- This level is far below the threshold for such an invasive procedure.
Neonatal Pharmacology Indian Medical PG Question 6: Neonatal tetanus prevention is best done by which antenatal measure?
- A. Tetanus toxoid (Correct Answer)
- B. Tetanus immunoglobulin
- C. Antibiotics (e.g., Penicillin)
- D. Antibiotics (e.g., Metronidazole)
Neonatal Pharmacology Explanation: ***Tetanus toxoid***
- **Tetanus toxoid vaccination** of pregnant women stimulates **active immunity** in the mother, leading to production of protective antibodies.
- These maternal IgG antibodies cross the placenta and provide **passive immunity** to the fetus/neonate, protecting against neonatal tetanus.
- Neonatal tetanus is often acquired through umbilical stump infection with *Clostridium tetani* spores in unhygienic delivery conditions.
- **WHO recommends** at least 2 doses of TT during pregnancy for prevention of neonatal tetanus.
*Tetanus immunoglobulin*
- **Tetanus immunoglobulin (TIG)** provides immediate **passive immunity**, but its effect is short-lived (3-4 weeks).
- It's used for **post-exposure prophylaxis** or treatment in individuals who are unimmunized or inadequately immunized.
- Not practical or recommended for routine antenatal prevention due to short duration, high cost, and need for repeated administration.
*Antibiotics (e.g., Penicillin)*
- While penicillin can be used as part of **tetanus treatment** to kill *Clostridium tetani* bacteria, it does not provide **preventive immunity** to the fetus.
- Antibiotics do not neutralize the tetanus toxin or provide antibodies for passive immunity.
- They have no role in antenatal prevention of neonatal tetanus.
*Antibiotics (e.g., Metronidazole)*
- **Metronidazole** is another antibiotic used to treat *Clostridium tetani* infection.
- Like penicillin, it does not confer **immunity** (active or passive) to the neonate.
- Not an effective antenatal measure for preventing neonatal tetanus.
Neonatal Pharmacology Indian Medical PG Question 7: A pediatrician was called for attending a new born baby in the labour ward. The serum unconjugated bilirubin of this baby was 33 mg/dL. Which of the following drug taken by mother in late 3rd trimester may have led to this problem?
- A. Ampicillin
- B. Azithromycin
- C. Cotrimoxazole (Correct Answer)
- D. Chloroquine
Neonatal Pharmacology Explanation: ***Cotrimoxazole***
- **Cotrimoxazole** (trimethoprim-sulfamethoxazole) can displace **bilirubin** from albumin-binding sites in the newborn, leading to increased levels of **unconjugated bilirubin** and a higher risk of kernicterus.
- Sulfonamides, a component of cotrimoxazole, are known to interfere with **bilirubin metabolism** and transport in neonates, particularly when taken by the mother late in pregnancy.
*Ampicillin*
- **Ampicillin** is a penicillin-class antibiotic generally considered safe during pregnancy and is not known to cause significant neonatal **hyperbilirubinemia**.
- Its mechanism of action does not involve competition for **albumin-binding sites** with bilirubin.
*Azithromycin*
- **Azithromycin** is a macrolide antibiotic commonly used in pregnancy and does not have a recognized association with significant **unconjugated hyperbilirubinemia** in newborns.
- It does not significantly affect the **bilirubin-albumin binding** in neonates.
*Chloroquine*
- **Chloroquine** is an antimalarial drug, and while generally avoided in the first trimester, it has not been linked to severe neonatal **hyperbilirubinemia** similar to that caused by sulfonamides.
- Its primary **side effects** in newborns are not related to bilirubin displacement.
Neonatal Pharmacology Indian Medical PG Question 8: A G2 P1 - 29-year-old female delivered a baby, but the baby died within 48 hours due to medical reasons. What drug will you advise to stop breast milk secretion?
- A. None of the options
- B. Ergot alkaloids
- C. Cabergoline (Correct Answer)
- D. Both B & C
Neonatal Pharmacology Explanation: ***Cabergoline***
- **Cabergoline** is a **non-ergot dopamine agonist** that effectively inhibits pituitary prolactin secretion, leading to the suppression of lactation.
- It works by acting on **D2 dopamine receptors** in the pituitary gland, thereby preventing milk secretion after delivery.
- It is the **preferred first-line agent** for lactation suppression due to its superior efficacy, better tolerability, longer half-life (allowing single or twice-daily dosing over 2 days), and lower side effect profile.
*None of the options*
- This option is incorrect because there are specific pharmacological agents available and recommended for **lactation suppression** in such circumstances.
- **Cabergoline** is a well-established and commonly used drug for this purpose.
*Ergot alkaloids*
- While **bromocriptine** (an ergot-derived dopamine agonist) was historically used for lactation suppression, it is no longer preferred.
- **Cabergoline** has largely replaced bromocriptine due to better tolerability, longer half-life, less frequent dosing, and fewer side effects (bromocriptine causes more nausea, vomiting, and orthostatic hypotension).
- Note: **Cabergoline itself is a non-ergot dopamine agonist**, making it pharmacologically distinct from ergot alkaloids.
*Both B & C*
- This option is incorrect because **cabergoline is not an ergot alkaloid**—it is a non-ergot dopamine agonist.
- While bromocriptine (an ergot derivative) can suppress lactation, **cabergoline alone** is the preferred choice with superior efficacy and safety profile.
- Combining or equating these agents is not standard clinical practice.
Neonatal Pharmacology Indian Medical PG Question 9: What is the treatment of choice for a 5-year-old child with bedwetting?
- A. No treatment
- B. Motivational therapy (Correct Answer)
- C. Imipramine
- D. Desmopressin
Neonatal Pharmacology Explanation: ***Motivational therapy***
- This is the **first-line active treatment** for **primary nocturnal enuresis** in children, involving encouragement, positive reinforcement (star charts), rewards, and education about bladder control.
- It focuses on **behavioral strategies** and can be highly effective with parental involvement.
- When intervention is pursued at age 5, motivational therapy is preferred over pharmacological options due to safety and effectiveness.
*No treatment*
- At age 5, **watchful waiting with reassurance** is often appropriate since nocturnal enuresis is common at this age (affects 15-20% of 5-year-olds) and has a **spontaneous resolution rate of 15% per year**.
- However, when the question asks for "treatment of choice," it implies active intervention rather than observation alone.
- Active behavioral therapy is preferred when bedwetting causes distress or affects the child's self-esteem.
*Imipramine*
- **Imipramine** is a **tricyclic antidepressant** with anticholinergic effects that can reduce bladder contractions, but it has significant side effects including **cardiac arrhythmias** and is **not first-line treatment**.
- It is typically reserved for children ≥7 years after behavioral interventions fail, due to its potential adverse effects and high relapse rate after discontinuation.
*Desmopressin*
- **Desmopressin** is an **antidiuretic hormone analog** that reduces urine production overnight.
- While effective, it is typically reserved for children ≥6 years who are unresponsive to behavioral therapy or for **short-term situational use** (e.g., sleepovers, camps).
- Side effects include potential **hyponatremia** and high relapse rate after discontinuation.
Neonatal Pharmacology Indian Medical PG Question 10: Which calcium channel blocker has the shortest duration of action?
- A. Diltiazem
- B. Amlodipine
- C. Nimodipine (Correct Answer)
- D. Verapamil
Neonatal Pharmacology Explanation: ***Nimodipine***
- Nimodipine is a **dihydropyridine calcium channel blocker** specifically formulated for cerebral vasodilation and used in conditions like **subarachnoid hemorrhage**.
- It has a relatively **short half-life** and rapid onset, making its duration of action shorter compared to other commonly used calcium channel blockers.
*Amlodipine*
- Amlodipine is known for its **long duration of action** and once-daily dosing due to its slow absorption and high bioavailability.
- Its prolonged action is beneficial for conditions like **hypertension and angina**, where sustained vasodilation is desired.
*Diltiazem*
- Diltiazem's duration of action is **intermediate** compared to other calcium channel blockers, often requiring BID to TID dosing for immediate-release formulations.
- It's a **non-dihydropyridine calcium channel blocker** with effects on both vascular smooth muscle and cardiac conduction.
*Verapamil*
- Verapamil also has an **intermediate duration of action**, similar to diltiazem, with immediate-release forms requiring multiple daily doses.
- As a **non-dihydropyridine calcium channel blocker**, it has significant effects on myocardial contractility and AV nodal conduction.
More Neonatal Pharmacology Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
